12 Results for "

IBT

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "IBT" in MCE Product Catalog:

Cat. No.: HY-13036A
CAS No.: 1022150-12-4
Purity:  99.59%
Target:  

Btk

Research Areas:  

Cancer

IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM .
loading...
    loading...
Cat. No.: HY-78727
CAS No.: 330786-24-8
Synonyms: IBT4A
Target:  

Drug Intermediate Btk

Research Areas:  

Inflammation/Immunology Cancer

Ibrutinib deacryloylpiperidine (IBT4A) is a derivative of an Ibrutinib (HY-10997) intermediate and an Ibrutinib impurity. Ibrutinib deacryloylpiperidine serves as a starting material and is used in the synthesis of a modified BTK inhibitor derivative via the Mitsunobu reaction .
loading...
    loading...
Cat. No.: HY-16660
CAS No.: 313553-47-8
Synonyms: IBT13131
Target:  

NEKs Apoptosis

Research Areas:  

Cancer

INH1 specifically disrupts the Hec1/Nek2 interaction via direct Hec1 binding. INH1 shows promising cancer inhibition activity both in vitro and in vivo .
loading...
    loading...
Cat. No.: HY-W291131
CAS No.: 27830-79-1
Synonyms: IBT
Target:  

HSV Orthopoxvirus

Research Areas:  

Infection

Isatin-β-thiosemicarbazone is a potent anti-poxvirus agent (including monkeypox virus, orthopoxvirus, vaccinia virus, etc). Isatin-β-thiosemicarbazone also is a potent herpes simplex virus (HSV) inhibitor. Isatin-β-thiosemicarbazone exhibits
loading...
    loading...
Cat. No.: HY-153803
CAS No.: 2864408-92-2
Purity:  98.99%
Research Areas:  

Cancer

GBD-9 is a degrader based on the E3 ubiquitin ligase CRBN that targets BTK and the G1 to S phase transition protein GSPT1. GBD-9 has both PROTAC and molecular glue properties by inducing ubiquitination and proteasomal degradation of target proteins. GBD-9 can efficiently degrade wild-type and mutant BTK (such as C481S mutation) and GSPT1. GBD-9 significantly inhibits tumor cell proliferation by inducing G1 phase arrest in cancer cells, downregulating anti-apoptotic proteins (BCL-2, MCL-1) and activating Caspase-3 to induce apoptosis. GBD-9 is mainly used in the research of hematological tumors such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML) .
GBD-9 is composed of E3 ubiquitin ligase ligand (pink part) 5-Aminothalidomide (HY-W023573), target protein ligand (blue part) Btk Inhibitor: IBT6A (HY-13036A), and PROTAC linker (black part) Nonanoic acid (HY-N7057).
loading...
    loading...
Cat. No.: HY-13036
CAS No.: 1412418-47-3
Purity:  98.18%
Target:  

Btk

Research Areas:  

Cancer

(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM .
loading...
    loading...
Cat. No.: HY-13036B
CAS No.: 1553977-42-6
Purity:  99.72%
Target:  

Btk

Research Areas:  

Cancer

IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM .
loading...
    loading...
Cat. No.: HY-13036C
CAS No.: 1807619-60-8
Target:  

Btk

Research Areas:  

Cancer

(Rac)-IBT6A hydrochloride is a racemate of IBT6A hydrochloride. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM .
loading...
    loading...
Cat. No.: HY-163963
CAS No.: 1970122-88-3
Research Areas:  

Cancer

IBT6A-CO-ethyne is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). IBT6A-CO-ethyne can be used for synthesis IBT6A (HY-13036A) .
loading...
    loading...
Cat. No.: HY-W591307
CAS No.: 2360561-66-4
Target:  

PROTAC Linkers

Research Areas:  

Cancer

P131 is a PROTAC molecule comprised of Pomalidomide-based cereblon ligand and IBT6A, linked by a PEG 3 chain. P131 can degrade both wild-type and C481S mutant BTK with nanomolar potencies.
loading...
    loading...
Cat. No.: HY-181546
Target:  

Btk PERK Syk HMG Family

Research Areas:  

Cancer

Ibt-DOX is a BTK inhibitor with an IC50 of 2.89 nM. Ibt-DOX is also a targeted covalent activated chemotherapeutic agent composed of the targeting ligand Ibrutinib (HY-10997), Doxorubicin (DOX) (HY-15142A), α-MAA (HY-W017180), and a linker (HY-Y0892). Ibt-DOX specifically binds to BTK and releases DOX, synergistically achieving BTK inhibition and chemotherapeutic killing, significantly enhancing toxicity against B-cell lymphoma cells and greatly reducing the toxic side effects of DOX on BTK-negative cells. Ibt-DOX can be used in lymphoma-related research .
loading...
    loading...
Cat. No.: HY-W017180
CAS No.: 72707-66-5
Synonyms: α-(Bromomethyl)acrylic acid; α-Methylated acrylamide; α-MAA
Target:  

Drug Intermediate

Research Areas:  

Cancer

2-(Bromomethyl) acrylic acid (α-MAA) is a component of Ibt-DOX (HY-181546) .
loading...
    loading...
  • 1